[Evaluation of the antihypertensive effect and tolerability of nadolol administered alone or in association with bendroflumethiazide].
The anti-hypertensive action and tolerability of single daily doses of 80 mg nadolol, or 80 mg nadolol and 5 mg bendroflumethiazide were assessed in 30 subjects with mild or moderate hypertension. In both experiments a significant reduction in arterial pressure was observed, while no undesirable effects were noted. The association of nadolol and bendroflumethiaxide not merely proved to have a greater anti-hypertensive effect than treatment with the beta-blocking agent alone, but also led to the normalisation of blood pressure values in a higher percentage of hypertensive subjects than when nadolol alone was administered. This particular drug combination is thus the treatment of choice for most patients with hypertension. The fact that the beta-blocking agent and the diuretic can be administered in a single daily dose clearly enhances the patient's compliance with the prescribed treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects
D011412:Propanolamines; D009248:Nadolol; D001539:Bendroflumethiazide
Valutazione dell'efficacia anti-ipertensiva e della tollerabilità del nadololo somministrato da solo o in associazione a bendroflumetiazide.